Stock Groups

FDA to review Merck Covid treatment ‘as quickly as they possibly can’


Anthony Fauci, National Institute of Allergy and Infectious Diseases (NIH) Director, is testifying before a Senate Health, Education, Labor and Pensions hearing. He will be giving an update on Federal efforts to counter COVID-19 at Dirksen Senate Office Building, Washington, DC, on May 11, 2021.

Jim Lo Scalzo | Getty Images

White House Chief Medical Advisor Dr. Anthony Fauci stated Friday that data will be reviewed by the Food and Drug Administration MerckRidgeback Biotherapeutics’ Covid oral antiviral is now available “as fast as possible” to help with emergency authorizations.

These companies stated their antiviralTreatment with molnupiravir reduced hospitalizations and deaths for patients suffering from mild to moderate Covid. 8 people died in 29 days after receiving the placebo during the phase III clinical trial. This included 775 patients who were randomized to either molnupiravir, or a placebo. The data that were released on Friday showed that none of the participants who had taken molnupiravir ever died.

Fauci stated that the FDA must be given time to examine the data carefully and to determine whether emergency use authorization is necessary. Fauci was speaking to CNBC’s CNBC.Closing Bell” They will do it as quickly and efficiently as possible. While I don’t know when, one thing I can predict is that it will happen as soon as it can be.

Merck and Ridgeback Biotherapeutics said 7.3% of the molnupiravir patients who were part of their phase three trial were admitted to hospital within 29-days, while only 14.1% of placebo victims were admitted or died. Each participant had at least one medical condition that could have increased the risk for severe Covid symptoms.

Molnupiravir would become the first antiviral oral to fight Covid if an FDA emergency authorization is granted. U.S. agreed to buy 1.7 million doses of molnupiravir. White House Coronavirus Response Coordinator Jeff Zients informed reporters Friday at a briefing that the government may purchase additional doses if approved.

Merck predicts that there will be 10,000,000 courses of Molnupiravir in its stock by 2021.

Fauci answered a question about whether or not molnupiravir will be available for everyone. Even though they are fully vaccinated, anyone can contract Covid. as vaccine effectiveness wanesHowever, they still offer protection from severe illness or death.

Fauci explained that he shouldn’t be able to predict what FDA will approve it for. “But, I’d assume that you’re already infected. It doesn’t matter if you have been vaccinated.

Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.